Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer

Br J Haematol. 2020 Aug;190(4):525-528. doi: 10.1111/bjh.16966. Epub 2020 Jul 22.
No abstract available

Keywords: Ruxolitinib; Tocilizumab; cytokine storm; secondary haemophagocytic lymphohistiocytosis; severe COVID.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • COVID-19 Drug Treatment*
  • COVID-19* / blood
  • COVID-19* / complications
  • COVID-19* / diagnostic imaging
  • Drug Therapy, Combination
  • Female
  • Humans
  • Interleukin-6 / antagonists & inhibitors*
  • Janus Kinases / antagonists & inhibitors*
  • Lymphohistiocytosis, Hemophagocytic* / blood
  • Lymphohistiocytosis, Hemophagocytic* / diagnostic imaging
  • Lymphohistiocytosis, Hemophagocytic* / drug therapy
  • Lymphohistiocytosis, Hemophagocytic* / etiology
  • Male
  • Middle Aged
  • Nitriles
  • Pyrazoles / administration & dosage*
  • Pyrimidines
  • SARS-CoV-2*
  • STAT Transcription Factors / analysis*

Substances

  • Antibodies, Monoclonal, Humanized
  • IL6 protein, human
  • Interleukin-6
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • STAT Transcription Factors
  • ruxolitinib
  • Janus Kinases
  • tocilizumab